Clinical trial · Interventional
The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults
NCT06876701CI-TRIAL-00087231not yet recruitingEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Leukemia | Acute Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental group
- interventionNames
- Drug: Bevacizumab
Primary outcomes (1)
- measure
- Negative conversion rate of evaluable residual lesions (MRD)
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients fully understand this study, voluntarily participate and sign an informed consent form (ICF); 2. Age: 18-75 years old (including boundary values of 18 and 75); 3. Clinically diagnosed adult Mixed Phenotype Acute Leukemia (WHO 2016 criteria) patients with CD19 positivity Exclusion Criteria: The subject's previous history of anti-tumor treatment meets one of the following conditions: 1. Individuals who have previously received bevacizumab 2. Individuals who have received CAR-T therapy or other gene modified cell therapies prior to screening; 3. Within 5 half lives of the first use of the investigational drug, having received anti-tumor treatment including surgery, chemotherapy, targeted therapy, or participating in other clinical trials and receiving clinical trial medication;
References
Publications (0)
Data not yet available
No reference posted for this study.